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pound of 7c was evaluated for its anxiolytic activities.
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The development of efﬁcient and novel synthetic methods for
the construction of polyfunctionalized heterocyclic compounds
have allocated a broad area of organic and medicinal chemis-
try (Domling and Ugi, 2000; Domling, 2006). Pyridines and
benzo[h]chromene derivatives have recently received consider-able attention due to their synthetic and pharmaceutical
importance. So different approaches for their synthesis have
been developed (Khafagy et al., 2002; El-Saghier et al.,
2007). Among these heterocycles, pyridine derivatives are an
important class in pharmaceutical discovery. 2-Amino-3-
cyanopyridines and 3-cyano-2-pyridones are known to have
diverse biological and pharmacological activities, particularly
antimicrobial (Temple et al., 1992), antidepressant (Murata
et al., 2005), cardiotonic (Shi et al., 2005) and anticancer activ-
ity (Abadi et al., 1999).
2. Results and discussion
These ﬁndings encouraged us to explore the synthesis
of 2-amino-4-aryl-6-alkyl(aryl)-3-cyanopyridines through a
Scheme 1 One-pot synthesis of 2-amino-4-aryl-6-alkyl(aryl)-3-
cyanopyridines in the presence of MgO.
S902 H. Sheibani et al.three-component reaction of a ketone such as acetone, cyclo-
hexanone or acetophenone, aryl aldehydes, malononitrile
and ammonium acetate in the presence of MgO as a highly
effective heterogeneous base catalyst (Scheme 1).
We found that a mixture of ketones 1, aryl aldehydes 2,
malononitrile and ammonium acetate in the presence of high
surface area MgO as a highly effective heterogeneous base cat-
alyst and as an inexpensive and readily available catalyst,
afforded 4,6-disubstituted-3-cyano-2(1H)-iminopyridines in
good to excellent yields and in a short experimental time (Ta-
ble 1). Many of the standard procedures require either longer
reaction times or in some cases lead to mixtures of products
and proceed in low yields (Murata et al., 2005; Shi et al.,
2005; Abadi et al., 1999).
The formation of products 4a–j can be rationalized by the
initial formation of imine I from aldehyde and ammoni-um
acetate, imine I reacts with alkylidenemalononitrile II (fromTable 1 Synthesis of 4a–i in the presence of base catalysts.
Com. No. [Without Catalyst] Commercial (MgO) High s
Time (h) Yield (%) Time (h) Yield (%) Time
4a 6 53 4 68 9
4b 6 44 5 50 10
4c 6 65 4 69 9
4d 6 45 4.5 68 9
4e 5 42 4 47 9
4f 8 59 4 62 7
4g 6 57 4 66 8
4h 8 38 5 55 10
4i 6 60 4 70 9
4j 6 41 4 65 8
5a 10 36 5 55 15
5b 10 35 4.5 60 12
5c 10 30 6 55 12condensation of aromatic aldehyde with malo- nonitrile) to
give III, followed by cycloaddition, isomerization, aromatiza-
tion to afford the 2-amino-3-cyanopyridine derivatives 4
(Scheme 2).
Encouraged by these results, we also developed our investi-
gation and replaced the activated phenolic compounds such as
a-naphthol or 4-chloro-1-naphthol 6 instead of ketones in
same conditions (Scheme 3).
The three-component reaction of malononitrile, aldehydes
and phenolic b-naphthol 8, is extended to the formation of
2-amino-fused chromenes 9a–c in the presence of magnesium
oxide (MgO) as a highly effective heterogeneous base catalyst
(Scheme 4).
2-Amino-chromenes and fused chromenes are an important
class of compounds found as the main components of many
naturally occurring products employed as cosmetics and pig-
ments (and utilized as potential biodegradable agrochemicals
(Hafez et al., 1987; Abdel Galil et al., 1982). Numerous reports
delineate the antitumor (Mohr et al., 1975), antimicrobial
activities (Bedair et al., 2000), and the central nervous system
(CNS) activity (Eiden and Denk, 1991) of these compounds.
Similarly, in recent years, considerable attention has been fo-
cused on the development of new methodologist to synthesize
many kinds of chromene ring system. These compounds are
generally prepared by reacting malononitrile, an aldehyde
and an activated phenol in organic solvents (i.e. acetonitrile,
ethanol) and in the presence of organic bases like piperidine,
which are frequently utilized in stoichiometric amounts (Ballini
et al., 2001; Khafagy et al., 2002). In the present study we
found that these compounds could be synthesized in a one step
procedure in the presence of high surface area MgO as a highly
effective heterogeneous base catalyst in excellent yields and in
a short reaction time (Table 2).
Three component reactions of salicylaldehyde, malononitri-
le and a ketone 11a–c in the presence of high surface area MgO
afforded the 4-(2-hydroxyphenyl)-6-alkyl-3-cyano-2(1H)-imi-
nopyridine derivatives 12a–c (Scheme 5). Structures of these
compounds were established on the basis of IR spectra which
showed the presence of CN at 2200–2210 cm1 and OH (phe-
nolic proup) at 3200–2900 cm1 (broad peak), respectively.
Hutchings and co-workers investigated the reaction of a
high surface area form of MgO as a catalyst for a number of
different Michael additions and Knoevenagel condensationsurface area (MgO) M. P. C M. P. reported C [Ref.]
(min) Yield (%) Observed
86 170–172 172–173 (Shi et al., 2005)
81 238–240 241–242 (Kambe et al., 1980)
79 255–257 258–260 (Kambe et al., 1980)
80 234–235 236–237 (Kambe et al., 1980)
83 182–184 180–182 (Shi et al., 2005)
85 194–196 195–196 (Shi et al., 2005)
84 159–160 159–60 (Shi et al., 2005)
85 187–188 188–190 (Abadi et al., 1999)
87 186–188 186–188 (Abadi et al., 1999)
84 216–218 217–219 (Abadi et al., 1999)
72 165–168 168–70 (Abadi et al., 1999)
78 235–237 240–42 (Abadi et al., 1999)
70 227–230 231–233 (Abadi et al., 1999)
Scheme 2 A reasonable mechanism for the formation of the products 4a–k.
Scheme 3 One-pot synthesis of 2-amino-3-cyano-4-aryl-4H-
benzo[h]-chromene in the presence of MgO.
Scheme 4 Three-component reaction of malononitrile, alde-
hydes and phenolic b-naphthol in the presence of MgO.
Scheme 5 Three component reaction of salicylaldehyde, malon-
onitrile and a ketone 11a–c in the presence of MgO.
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2005). We sought to develop a route that is simple to perform
and that allows to reuse the catalyst for a number of times, andTable 2 Synthesis of 7a–g and 9a–c in the presence of base catalys
Com. No. [Without Catalyst] Commercial (MgO) High surface
Time (h) Yield (%) Time (h) Yield Time (min)
7a 6 50 3.5 70 5
7b 6 45 3.5 70 8
7c 6 45 4 68 8
7d 6 40 4 65 12
7e 4 60 3 75 7
7f 5 45 3.5 65 9
7g 5 50 3.5 65 8
9a 6 65 4 70 9
9b 6 62 4 69 5
9c 6 60 4 66 12was tried to focus on solvents, where the product will be pre-
cipitated out from the reaction mixture when the reaction is
completed. As shown in Tables 1 and 2 the yields of reactions
are markedly affected by the catalyst, and optimum results
were obtained when reactions were run in dimethylformamide
(DMF) and in the presence of high surface area MgO. In order
to optimize the reaction conditions for preparing compounds
4, 5, 7, 9 and 12 the effect of base catalyst and solvents such as
water, ethanol, acetonitrile and dimethylformamide under
different reaction conditions were investigated. Yields are rel-
atively higher when DMF was used as a solvent in comparison
with other solvents. We also attempted to reuse the catalyst in
three-component reaction of acetone, benzaldehyde, malono-
nitrile and ammonium acetate in dimethylformamide (DMF)
as a solvent to prepare compound 4d for three times. It should
be noted that the catalytic activity also decreased after each use
(Table 3).
The compounds 4a–f are known in the literature (Abadi
et al., 1999; Kambe et al., 1980; Hafez et al., 1987; Abdel Galilts.
area (MgO) M. P. C observed M. P. reported C [Ref.]
Yield
97 237–240 239.5–241 (Ballini et al., 2001)
95 212–213 214.5–216 (Ballini et al., 2001)
95 231–233 231–232.5 (Ballini et al., 2001)
91 183-185 183–184.5 (Ballini et al., 2001)
95 242–244 246 (Khafagy et al., 2002)
92 221–223 224 (Khafagy et al., 2002)
95 224–226 226 (Khafagy et al., 2002)
88 206-208 207–208.5 (Ballini et al., 2001)
91 189–190 188–189 (Ballini et al., 2001)
83 191–193 190–191.5 (Ballini et al., 2001)
Table 3 Reusability of high surface area MgO.
Entry Catalyst Time (min) Yield (%)
1 MgO (1st use) 9 80
2 MgO (2nd use) 15 70
3 MgO (3rd use) 25 50
Figure 1 Effects of vehicle (Toeen 80%+ CMC) and com-
pound 7c (3.7, 7.4 and 14.8 mg/kg) on total entries. Data are
presented as mean ± SEM, (one-way ANOVA following by
Tukey test. n= 7).
Figure 2 Effects of vehicle (Toeen 80%+ CMC) and com-
pound 7c (3.7, 7.4 and 14.8 ml/kg) on open arm time. Control.
Data are presented as mean ± SEM. (one-way ANOVA following
by Tukey test. n= 7). *P< 0.05 vs dose 7.4.
S904 H. Sheibani et al.et al., 1982). The IR spectra and melting point of all known
compounds were consistent with those reported in the litera-
ture. Structures 4g–i were established on the basis of IR mea-
surements which showed the presence of CN at the region
2235–2238 cm1 and two sharp bands at 3500–3450 and
3390–3380 cm1 due to asymmetric and symmetric vibrations
of the NH2 group. The
1H and 13C NMR and mass spectra
were also in accordance with the proposed structures.
2.1. Pharmacology
Previous study has been shown that the chromenes and fused
chromenes have biological effects, one of the site for the action
of this compound is the central nervous system (CNS) (Eiden
and Denk, 1991; El-Agrody et al., 2000; Bianchi and Tava,
1987; Hogg, 1996; Taylor et al., 1998; Smith et al., 1998).
Anxiety disorders are the most common mental illnesses in
the world and become a very important area of research inter-
est in psychopharmacology. With regard to the documented
history of these compounds in relation to their effect on anxi-
ety the aim of the present study was to evaluate the probably
anxiolytic effects of the new heterocyclic 2-amino-3-cyano-4-
(4-chlorophenyl)-4H-benzo[h]-chromene (C19H13ClNO) 7c on
the Elevated Plus-Maze (EPM).
3. Material and methods
3.1. Model of anxiety
Male NMRI rats (Pasteur, Tehran) 250–300 g were housed in
cage (seven in each cage) and kept in a room with controlled
temperature (22–25 C).The Rats were maintained on a 12:12
light-dark cycle and had access to food and water ad libitum.
Test was performed only after the rat had acclimated to the
above environment for at least 7 days. All experiments were
carried out between 08:00 and 13:00. Each rat received a single
intraperitoneal (ip) injection of compound 7c (different doses)
or vehicle CMC+ Toeen 80% and was tested once in the
EPM. All procedures were approved by the Ethical committee
of the Shahid Bahonar University of Kerman and conducted
in accordance with the internationally accepted principles for
laboratory animal use and care.
3.2. Elevated Plus-Maze
The EPM test is described in detail elsewhere (Abadi et al.,
1999; Abdel Galil et al., 1982). Brieﬂy, the apparatus com-
prised two open arms (35 · 5 cm) and two closed arms
(30 · 5 · 15 cm) that extended from a common central plat-
form (5 · 5 cm). The ﬂoor and walls of each arm were made
of wood and painted black. The entire maze was elevated to
a height of 60 cm above ﬂoor level. Testing was conducted in
a quiet room illuminated only by a dim light. Rats were givena single ip dose of compound 7c 30 min before their placement
on the EPM. To begin a test session, the animals were placed
on the open arm facing the center of the maze. An entry into
an arm was deﬁned as the animal placing all four paws over
the line marking that area. The number of entries and the time
spent in the open arm closed arms were recorded during a
5 min test period. The percentage of open arm entries (open/
total · 100 entries was calculated for each animal · 24). Be-
tween each trial, the maze was wiped clean with a damp sponge
and dried with paper towels.
3.3. Statistics
Statistical analysis performed using one-way analysis of vari-
ance (ANOVA) with post hoc TUKEY test. P< 0.05 was
considered signiﬁcant. All data are expressed as mean ± SEM.
3.4. Results
Related to total entries there was no signiﬁcant difference
between groups (Fig. 1).
The compound 7c at a dose of 7.4 mg/kg signiﬁcantly
decreased the percentage of time spent (P< 0.05) in the open
arms (Fig. 2).
4. Conclusions
In conclusion, we have developed a general and easy method
for the synthesis of 4,6-disubstituted-3-cyano-2(1H)-imino-
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cyanide derivatives in the presence of high surface area MgO
as a highly effective heterogeneous base catalyst. The catalysts
show environmental friendly character, which is inexpensive
and easily obtained. EPM is a model which uses the natural
fear of rodents to avoid open and elevated places. The results
show that vehicle did not statistically change the measured
EPM parameter. The compound 7c decreased open arm time,
this behavioral alteration induced by 7c in the EPM provided
anxiogenes effect at 7.4 mg/kg, so we can conclude that this
compound has stimulation effect rather than sedation. The re-
sults also show that compound 7c at all doses did not statisti-
cally change total entries. This effect further conﬁrms the
absence of sedation properties of 7c. Based on the core compo-
sition of this heterocycle, the anxiolytic activity was expected,
but the reverse was observed.
5. Experimental section
Melting points were measured on a Gallenkamp melting point
apparatus and are uncorrected. IR spectra were measured on a
Mattson 1000 FT-IR spectrometer. The proton and carbon
NMR spectra were recorded with a BRUKER DRX-500
AVANCE spectrometer at 500 and 125.77 MHz, respectively.
Mass spectra were recorded on a MS-QP2000A Shimadzu
mass spectrometer operating at an ionization potential of
70 eV. Elemental analyses were performed using a Heracus
CHN-O-Rapid analyzer.
5.1. Preparation of high surface area MgO
The catalyst used in this study was obtained by rehydrated
Mg(OH)2 at 450 C for 2 h. A calcination temperature of
400–500 C gave maximum conversion. When the catalyst
was calcined above 500 C, the activity of MgO decreased
and continued to decrease as the calcination temperature in-
creased. The maximum surface area was obtained after calcin-
ing the samples at 400–500 C (Chunli et al., 2005).
5.2. General procedure for compounds 4 and 5
A mixture of aldehyde (2 mmol), appropriate ketone (2 mmol),
ammonium acetate (2 mmol) and malononitrile or ethyl cya-
noacetate (2 mmol), and MgO (50 mg) in DMF (20 mL) was
reﬂuxed with stirring for the time reported in Table 1 (the pro-
gress of the reaction being monitored by TLC and hexane/
ethyl acetate was used as an eluent). After completion of the
reaction the catalyst was separated from the reaction mixture
by centrifugation and then was poured into ice cold water;
the crude product was ﬁltered, dried and recrystallized from
96% ethanol.
5.3. General procedure for compounds 7 and 9
A mixture of aldehyde 1 (2 mmol), malononitrile 2 (2 mmol),
phenolic compound 4 (2 mmol) and MgO (50 mg) in DMF
(20 mL) was reﬂuxed with stirring for the time reported in Ta-
ble 2. After completion of the reaction, as indicated by TLC,
MgO was removed by ﬁltration and excess dimethylformamide
was distilled off. The crude product so obtained was recrystal-
lized from ethanol to afford the pure product.5.4. General procedure for compounds 12
The foregoing method was carried out except that aldehyde
and phenolic compounds were replaced by salicylaldehyde
(Scheme 4).
5.4.1. Spectral data for selected compounds
5.4.1.1. 4-(4-Chlorophenyl)-6-methyl-2-amino-3-cyano-pyridine
(4a). Colorless crystals; mp 170–172 C. mmax(KBr): 3390 and
3313 (NH2), 3070 (ArH), 2211 (CN)cm
1; dH (500 MHz,
DMSO-d6): 7.58 (2H, d,
3JHH = 7.9 Hz, ArH), 7.58 (2H, d,
3JHH = 7.9 Hz, ArH), 6.85 (2H, s, NH2), 6.62 (1H, s, PryH),
2.36 (3H, s, CH3) ppm.
5.4.1.2. 4-(4-Methoxyphenyl)-6-phenyl-2-amino-3-cyano-pyri-
dine (4e). Colorless crystals; mp 182–184 C. mmax(KBr):
3452 and 3307 (NH2), 3120 (ArH), 2210 (CN) cm
1; dH
(500 MHz, DMSO-d6): 8.10–8.12 (2H, m, ArH), 7.55 (2H, d,
J= 8.0 Hz, ArH), 7.50–7.49 (3H, m, ArH), 7.32 (1H, s,
CH), 7.10 (2H, d, J= 8.0 Hz, ArH), 6.87 (2H, s, NH2), 3.85
(3H, s, OCH3) ppm.
5.4.1.3. 6-(2,4-Dimethoxyphenyl)-4-phenyl-2-amino-3-cyano-
pyridine (4h). Pale yellow crystals; mp 187–188 C. mmax(KBr):
3480, 3450 and 3300 (NH2), 3075 (ArH), 2200 (CN) cm
1. dH
(500 MHz, DMSO-d6): 7.85–6.70 (m, 11H, ArH and NH2),
3.82 (6H, s, 2 and 4-OCH3) ppm.
5.4.1.4. 6-(2,4-Dimethoxyphenyl)-4-phenyl-3-cyano-(1H)-
pyridinone (5a). Pale yellow crystals; mp 165–168 C.
mmax(KBr): 3550–3200 (NH2), 2212 (CN) cm
1. dH
(500 MHz, DMSO-d6): 12.4 (1H, broad NH), 7.65–6.50 (m,
9H, ArH), 3.84 (6H, s, 2 and 4-OCH3) ppm.
5.4.1.5. 2-Amino-3-cyano-4-(4-nitrophenyl)-4H-benzo[h]-chro-
mene (7a). Yellow crystals; mp 237–240 C. mmax(KBr): 3480-
3300 (NH2), 2211 (CN) cm
1. dH (500 MHz, DMSO-d6): 8.30
(d, 1H, J= 7.7 Hz, H-10 or H-7), 8.15 (d, 2H, J= 8.5 Hz, H-
30 and H-50 or H-20 and H-60), 7.80 (d, 1H, J= 7.6 Hz, H-7
or H10), 7.60 (d, 1H, J= 8.5 Hz, H-6 or H-5), 7.30 (d, 2H,
J= 8.5 Hz, H-20 and H-60 or H-30 and H-50), 7.45–7.70
(m, 2H, H-8 and H-9), 7.30 (s, 2H, NH2), 7.00 (d, 1H,
J= 8.5 Hz, H-5 or H-6), 5.20 (s, 1H, H-4) ppm.
5.4.1.6. 2-Amino-4-(2-hydroxyphenyl)-6-methyl-3-pyridylcya-
nide (12a). A 0.40 g. red crystals, yield 90%; mp 234–
236 C; mmax(KBr): 3354, 3205 (broad, NH2 and OH), 2212
(CN), 1617 (C‚N), 1517 (Ar) cm1; dH (500 MHz, DMSO-
d6): 10.01 (1H, s, OH), 8.83–.25 (7H, m, arom and NH2),
1.77 (3H, s, CH3); dC (125 MHz, DMSO-d6)160.31, 159.37,
157.94, 151.30, 129.88, 128.64, 124.54, 120.35, 117.50, 117.12,
86.57, 71.05, 23.49 (CH3).; MS, m/z (%): 225 (M
+, 20), 101
(18), 83 (16), 77 (18), 59 (30), 43 (100). Anal. Calcd. For
C13H11N3O: C, 69.32; H, 4.92; N, 18.65%. Found: C, 69.05;
H, 4.81; N; 18.35.
5.4.1.7. 2-Amino-4-(2-hydroxyphenyl)-6-(4-methoxyphenyl)-3-
pyridylcyanide (12b). A 0.53 g. red crystals, yield 85%; mp
238–240 C; mmax(KBr): 3329, 3205 (broad, NH2 and OH),
2212 (CN), 1620 (C‚N), 1517 (Ar) cm1; dH (500 MHz,
DMSO-d6): 9.90 (1H, s, OH), 8.41–6.89 (11H, m, arom and
S906 H. Sheibani et al.NH2), 3.39 (3H, s, CH3); dC (125 MHz, DMSO-d6) 167.77,
163.12, 160.18, 155.08, 151.85, 143.04, 132.72, 129.40, 124.66,
123.30, 119.30, 116.43, 116.35, 92.19, 81.01, 59.35 (CH3).;MS,
m/z (%): 317 (M+, 10), 312 (8), 209 (34), 121 (100), 83 (15), 77
(29), 59 (30). Anal. Calcd. For C19H15N3O2: C, 71.91; H, 4.76;
N, 13.24%. Found: C, 71.65; H, 4.56; N; 12.95.
5.4.1.8. 2-Amino-6-(2-chlorophenyl)-4-(2-hydroxyphenyl)-3-
pyridylcyanide (12c). A 0.51 g red crystals, yield 80%; mp
235–237 C; mmax(KBr): 3429, 3180 (broad, NH2 and OH),
2212 (CN), 1666 (C‚N), 1517 (Ar) cm1; dH (500 MHz,
DMSO-d6): 10.09 (1H, s, OH), 8.82(d, 1H, J= 6.8 Hz,
ArH), 8.40 (s, 1H, H5), 7.70–6.98 (9H, m, arom and NH2);
dC (125 MHz, DMSO-d6) 163.23, 160.97, 156.01, 152.80,
144.01, 140.97, 133.77, 129.30, 125.96, 124.28, 120.30, 117.40,
116.43, 116.35, 94.34, 79.89. MS, m/z (%): 321 (M+, 25),
285 (10), 77 (100), 59 (35). Anal. Calcd. For C18H12ClN3O:
C, 67.19; H, 3.76; N, 13.06%. Found: C, 66.87; H, 3.51; N;
12.85.Acknowledgment
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